These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 30877436)

  • 21. Cannabinoids and brain injury: therapeutic implications.
    Mechoulam R; Panikashvili D; Shohami E
    Trends Mol Med; 2002 Feb; 8(2):58-61. PubMed ID: 11815270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown.
    Reggio PH
    Curr Med Chem; 2010; 17(14):1468-86. PubMed ID: 20166921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioelectronic sensing platform emulating the human endocannabinoid system for assessing and modulating of cannabinoid activity.
    Cho H; Oh DE; Nam Y; Lee SH; Kim TH
    Biosens Bioelectron; 2024 Nov; 264():116686. PubMed ID: 39173339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The molecular basis for neuroimmune receptor signaling.
    Rogers TJ
    J Neuroimmune Pharmacol; 2012 Dec; 7(4):722-4. PubMed ID: 22935971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.
    Lowe H; Toyang N; Steele B; Bryant J; Ngwa W
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabinoids, endocannabinoids, and related analogs in inflammation.
    Burstein SH; Zurier RB
    AAPS J; 2009 Mar; 11(1):109-19. PubMed ID: 19199042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
    Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
    Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phytocannabinoids and endocannabinoids.
    Fisar Z
    Curr Drug Abuse Rev; 2009 Jan; 2(1):51-75. PubMed ID: 19630737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthetic and endogenous cannabinoids protect retinal neurons from AMPA excitotoxicity in vivo, via activation of CB1 receptors: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
    Kokona D; Thermos K
    Exp Eye Res; 2015 Jul; 136():45-58. PubMed ID: 25989217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic potential of the endocannabinoid system in the brain.
    Ramos JA; González S; Sagredo O; Gómez-Ruiz M; Fernández-Ruiz J
    Mini Rev Med Chem; 2005 Jul; 5(7):609-17. PubMed ID: 16026307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide.
    Cano C; Páez JA; Goya P; Serrano A; Pavón J; Rodríguez de Fonseca F; Suardíaz M; Martín MI
    Eur J Med Chem; 2009 Dec; 44(12):4889-95. PubMed ID: 19762126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocannabinoids in nervous system health and disease: the big picture in a nutshell.
    Skaper SD; Di Marzo V
    Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3193-200. PubMed ID: 23108539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
    Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
    J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.
    Hegde VL; Hegde S; Cravatt BF; Hofseth LJ; Nagarkatti M; Nagarkatti PS
    Mol Pharmacol; 2008 Jul; 74(1):20-33. PubMed ID: 18388242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.
    Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M
    Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phytocannabinoid Pharmacology: Medicinal Properties of
    Sampson PB
    J Nat Prod; 2021 Jan; 84(1):142-160. PubMed ID: 33356248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond.
    Pertwee RG
    Addict Biol; 2008 Jun; 13(2):147-59. PubMed ID: 18482430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydrophobic Ligand Entry and Exit Pathways of the CB1 Cannabinoid Receptor.
    Jakowiecki J; Filipek S
    J Chem Inf Model; 2016 Dec; 56(12):2457-2466. PubMed ID: 27966915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocannabinoids: new targets for drug development.
    Di Marzo ; Bisogno T; De Petrocellis L
    Curr Pharm Des; 2000 Sep; 6(13):1361-80. PubMed ID: 10903398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
    Porter AC; Sauer JM; Knierman MD; Becker GW; Berna MJ; Bao J; Nomikos GG; Carter P; Bymaster FP; Leese AB; Felder CC
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1020-4. PubMed ID: 12023533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.